
The Food and Drug Administration's safety review of mifepristone is expected to stretch into next year, according to an Oct. 7 court filing, prompting disappointment from pro-life groups.
The post FDA Expects To Draft Mifepristone Safety Review Next Year; Pro-Life Groups Call It ‘Insufficient’ appeared first on The Tablet.
Espace publicitaire · 300×250








